These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1354036)

  • 41. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
    Shastri M; Alla L; Sabaratnam M
    J Psychopharmacol; 2006 Nov; 20(6):863-7. PubMed ID: 16891339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroleptic malignant syndrome presenting with acute renal failure.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1074-5. PubMed ID: 18281139
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses.
    Salvesen C; Vaksdal K
    PDM; 1974; 5-6(9-12;1-8):10-4. PubMed ID: 4156935
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
    Chen CK; Chen YC; Huang YS
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypothermia in 2 patients treated with atypical antipsychotic medication.
    Parris C; Mack JM; Cochiolo JA; Steinmann AF; Tietjen J
    J Clin Psychiatry; 2001 Jan; 62(1):61-3. PubMed ID: 11235936
    [No Abstract]   [Full Text] [Related]  

  • 46. Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention.
    Perkins DO
    CNS Spectr; 2007 Oct; 12(10 Suppl 18):10-3. PubMed ID: 19322959
    [No Abstract]   [Full Text] [Related]  

  • 47. Antipsychotic polypharmacy: do benefits justify the risks?
    Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
    Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
    [No Abstract]   [Full Text] [Related]  

  • 48. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects.
    Strous RD; Alvir JM; Robinson D; Gal G; Sheitman B; Chakos M; Lieberman JA
    Schizophr Bull; 2004; 30(2):265-78. PubMed ID: 15279045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating depression in schizophrenic patients.
    Seeman MV; McGee H
    Am J Psychother; 1982 Jan; 36(1):14-22. PubMed ID: 6123265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Letter to the Editor: haloperidol but not dopamine rapidly induces neuronal death: comments on 'A systematic review of the effects of antipsychotic drugs on brain volume'.
    Grant P
    Psychol Med; 2013 Jul; 43(7):1568. PubMed ID: 23651623
    [No Abstract]   [Full Text] [Related]  

  • 51. The art of rational neuroleptic therapy.
    Ayd FJ
    Isr J Psychiatry Relat Sci; 1983; 20(4):292-8. PubMed ID: 6147324
    [No Abstract]   [Full Text] [Related]  

  • 52. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
    Morlán-Coarasa MJ; Arias-Loste MT; Ortiz-García de la Foz V; Martínez-García O; Alonso-Martín C; Crespo J; Romero-Gómez M; Fábrega E; Crespo-Facorro B
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):3947-3952. PubMed ID: 27620899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Atypical antipsychotic agents in the adolescent: what implications for the future?].
    Cohen D
    Encephale; 2011 Sep; 37(4 Suppl 4):H15-7. PubMed ID: 22108183
    [No Abstract]   [Full Text] [Related]  

  • 54. Antipsychotics in adolescent-onset psychosis: a work in progress.
    James AC; Broome MR
    Lancet Psychiatry; 2017 Aug; 4(8):e16-e17. PubMed ID: 28748801
    [No Abstract]   [Full Text] [Related]  

  • 55. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report.
    Chan YC; Miller KM; Shaheen N; Votolato NA; Hankins MB
    Schizophr Res; 2005 Oct; 78(2-3):343-5. PubMed ID: 16085390
    [No Abstract]   [Full Text] [Related]  

  • 56. [Therapy of endogenous attack-like adolescent psychoses: main principles and approaches].
    Kaleda VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):4-11. PubMed ID: 17069055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
    Kasper S; Küfferle B
    J Clin Psychopharmacol; 1998 Aug; 18(4):353-6. PubMed ID: 9690709
    [No Abstract]   [Full Text] [Related]  

  • 58. The clinical use of antipsychotic medications.
    Coyle JT
    Med Clin North Am; 1982 Sep; 66(5):993-1009. PubMed ID: 6127455
    [No Abstract]   [Full Text] [Related]  

  • 59. Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms.
    Barch DM; Carter CS; MacDonald AW; Braver TS; Cohen JD
    J Abnorm Psychol; 2003 Feb; 112(1):132-43. PubMed ID: 12653421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.